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Radiation-induced peripheral neuropathy is a chronic handicap, frightening because progressive and usu-
ally irreversible, usually appearing several years after radiotherapy. Its occurrence is rare but increasing
with improved long-term cancer survival.
The pathophysiological mechanisms are not yet fully understood. Nerve compression by indirect exten-
sive radiation-induced ﬁbrosis plays a central role, in addition to direct injury to nerves through axonal
damage and demyelination and injury to blood vessels by ischaemia following capillary network failure.
There is great clinical heterogeneity in neurological presentation since various anatomic sites are irra-
diated. The well-known frequent form is radiation-induced brachial plexopathy (RIBP) following breast
cancer irradiation, while tumour recurrence is easier to discount today with the help of magnetic reso-
nance imaging and positron emission tomography. RIBP incidence is in accordance with the irradiation
technique, and ranges from 66% RIBP with 60 Gy in 5 Gy fractions in the 1960s to less than 1% with
50 Gy in 2 Gy fractions today. Whereas a link with previous radiotherapy is forgotten or difﬁcult to estab-
lish, this has recently been facilitated by a posteriori conformal radiotherapy with 3D-dosimetric recon-
stitution: lumbosacral radiculo-plexopathy following testicular seminoma or Hodgkin’s disease
misdiagnosed as amyotrophic lateral sclerosis.
Promising treatments via the antioxidant pathway for radiation-induced ﬁbrosis suggest a way to
improve the everyday quality of life of these long-term cancer survivors.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.Radiotherapy and Oncology 105 (2012) 273–282Long-term cancer survivors have an unavoidable tissue trace of
their previous treatment, especially radiotherapy (RT), which is
most often clinically asymptomatic [1]. Some patients have radia-
tion damage in normal tissues affecting the functional or vital
prognosis. The symptoms are related to the irradiated volume
and their severity depends on the intensity of the underlying ﬁbro-
tic process, combined with direct toxicity of RT for speciﬁc cells,
depending on the organ concerned. Involvement of the peripheral
nervous system structures is rare, although state-of-the-art epide-
miological studies are lacking [2], but has a considerable impact on
quality of life in patients considered to be cured of their cancer.
Radiation-induced peripheral neuropathy (RIPN) is better
understood today through recognition of various clinical presenta-
tions corresponding to different damage to nerve roots, nerve
plexus or nerve trunks, and using radiological methods to discount
tumour recurrence including magnetic resonance imaging (MRI),was searched for articles
cluding ‘‘radiotherapy injury’’
chial plexopathy or plexitis’’
d book chapters of particular
érapie, Hôpital Saint Louis, 1,
anian).
er CC BY-NC-ND license.positron emission tomography (PET) and a posteriori conformal
RT with 3D-dosimetric reconstitution [3]. Recent histological forms
in addition to the classic ﬁbrosis, consist in description of multiple
cavernomas of the nerve roots [4].
In the ﬁrst part of the paper, we review themechanisms of RIPN,
particularly focusing on the mechanisms of ﬁbrosis, which is a
main causative factor and therapeutic target. In the second part,
we review the general context of RIPN diagnosis and then describe
the speciﬁc clinical and laboratory features according to the ana-
tomic site of injury. The last part of the article considers existing
and future treatment options.
Literature chosen in this article explore several decades of pa-
pers, not written with the same requirements and technical de-
tails: old clinical series with many uncertainties, drove us to
choose the very plausible and appropriate explanations.Mechanisms underlying RIPN
Pathophysiology
RIPN is delayed local damage to mature nerve tissue which is
partly attributable to initial microvascular injury, then radiation-
induced ﬁbrosis (RIF) combined with speciﬁc neurological injury
[5]. RIF is a dynamic process related to perturbations at various
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tion to sclerosis (Fig. 1), and is characterised by gradual stepwise
worsening over a period of several years: an early asymptomatic
preﬁbrotic phase with chronic inﬂammation, then an organised ﬁ-
brotic phase of extracellular matrix deposits, and a late ﬁbro-
atrophic poorly vascularised phase with retractile ﬁbrosis [1].
The mechanisms consist of a vicious circle built on several imbal-
ances including ﬁbroblast proliferation, extracellular matrix depo-
sition, ampliﬁed by cytokines such as TGFß1 and CTGF. The
smallest chief participant has been identiﬁed as oxygen free radi-
cals (reactive oxygen species). Radicals are normally involved in
physiological functions such as cell differentiation, proliferation
and inﬂammation, but excess production may result in pathologi-
cal stress to tissues as induced by physicochemical damage, infec-
tious agents and deﬁcient antioxidant defences. When the damage
level rises so much that the oxidative stress response is transiently
overwhelmed, ﬁbrogenesis becomes possible. Subsequent addi-
tional stress, chronic or brief and repeated resulting in abnormal
radical concentrations, may enhance production of reactive oxygen
species, thus helping to extend and intensify the ﬁbrotic process.
RIF pathogenesis [review in 1] has been highly debated. An old
vascular concept based on a theory of gradual ischaemia–hypoxia
was developed to account for capillary network destruction after
RT. More recent ideas consider reactions of endothelial cells to
RT with procoagulant pro-inﬂammatory effects of thrombin, and
changed microvascularisation in relation to intermittent rather
than chronic hypoxia, inducing hypoxic inducible factor, then neo-
angiogenesis possibly leading to telangiectasia [6]. However,
although these vascular dysfunctions are involved in generating
RIF, their role seems indirect in the established ﬁbrotic phase.
The ﬁbroblastic stromal concept sheds further light on RIF, in terms
of continuous attack by reactive oxygen species leading to ﬁbro-
genesis [1].
Sensitivity of the peripheral nerves to radiation. Early descrip-
tions of RIPN lesions were based on experimental data using single
high-dose RT with a pattern of damage in a direct dose–effect rela-
tionship [2]. In the acute phase, the irradiated nerve shows tran-
sient electrophysiological and biochemical changes combined
with an altered vascular permeability. Delayed effects enhance a
disorganised patchwork structure in the irradiated volume includ-Fig. 1. Radiation-induced ﬁbing direct axonal injury and demyelination, extensive ﬁbrosis with-
in and surrounding nerve trunks, and ischaemia by injury to
capillary networks supplying the nerves compensated for by
neovascularisation.Risk factors
Factors affecting the risk, severity, and nature of RIPN in pa-
tients are not speciﬁc. Several RT-related factors have been identi-
ﬁed: ﬁfty years ago low-energy machines used a short source-to-
skin distance (cobalt 60 cm), alternating treated ﬁelds with steep
dose gradients within the body, and body position displacement
(the RT machine did not turn around the patient) between each
RT ﬁeld favouring overlapping ﬁelds with a three-ﬁeld technique
[7,8]; large total dose (>50 Gy to plexus, >60 Gy to cranial nerves)
[9–11], large dose per fraction (P2.5 Gy, stereotactic radiosurgery)
[10,12], RT volume including a large proportion of nerve ﬁbres [13],
heterogeneous high-dose distribution [3], hot spot high dose (ﬁeld
junctions), salvage RT of previously treated areas, in intracavitary
radium source [14], or after IORT boost.
Combined treatment-related factors are the following: surgery in
the case of haematoma or chronic infection and extended lymph
node dissection (axillary, retroperitoneal or iliac nodes); concomi-
tant or previous neurotoxic chemotherapy (cisplatin, vinca alka-
loids, taxanes) or concomitant chemotherapy with intrathecal
methotrexate. Patient-related factors are: young or advanced age,
obesity, co-morbidity factors such as high blood pressure, diabetes
mellitus, dyslipidaemia, combined peripheral neuropathy (dia-
betic, alcoholic, genetic. . .) or arteritis (smoking, multiple sclero-
sis), pre-existing collagen vascular diseases and hypersensitive
patients [1].Clinical and paraclinical neurological features
Experience shows that when complications arise years later, in
cancer survivors, the link with previous RT is forgotten or difﬁcult
to establish since symptoms are nonspeciﬁc, and so the diagnosis is
made after a long series of medical consultations and tests, some-
times invasive (lumbar puncture, nerve biopsy, etc.). In the absencerosis: pathophysiology.
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analysis of symptoms, electrophysiological ﬁndings, MRI and PET
scan. Collaboration between the neurologist and the radiotherapist
allows determination of whether the neurological symptoms can
be related to nerve damage within the irradiation volume, namely
with a dosimetric reconstitution [3]. The diagnosis is guided by
cutaneous atrophy with subcutaneous ﬁbrosis and tattoo marks
identifying the previous irradiated ﬁelds, and possible combined
extra-neurological complications as sterno-clavicular osteoradio-
necrosis, radiation-induced cardiopathy, enteritis or multiple basal
cell skin carcinoma. The diagnostic work-up aims to eliminate a
cancer recurrence, but the clinical picture may also mimic many
neurological diseases. Exceptional cases of peripheral nerve tu-
mour, especially schwannoma, [15] with a developing painful mass
in the irradiated volume and a rapidly (months) increasing neuro-
logical deﬁcit, have been reported from 4 to 40 years after RT [16].
Neurotoxicity depends on the affected anatomic site of previous
irradiation: we describe and classify these various topographic
forms [17].Cranial nerve injury predominantly involves the optic nerve
Cranial nerve injury is described after RT for intracranial and
extracranial tumours: central nervous tumours as pituitary ade-
noma, craniopharyngioma, chiasmal glioma, frontal meningioma,
orbit tumours, and head and neck cancers [18]. Technical progress
in RT protocols has reduced its incidence in the last decades [9].
When radiation-induced optic neuropathy affects the anterior part
of the optic nerve, ophthalmological ﬁndings are those of acute
ischaemic anterior optic neuropathy with acute loss in visual acu-
ity. However, chronic damage to the posterior portion of the optic
nerve or chiasma is the most frequent (posterior radiation-induced
optic neuropathy), with gradual impairment of visual acuity over
1–14 years after RT [18]. Hypoglossal palsy is the second most fre-
quently reported cranial neuropathy: 19 out of 35 patients (54%)
after RT in the 1960s [19]. Classically, patients develop tongue
hemiatrophy, fasciculations and deviation when protracting the
tongue, 1–10 years after RT for head and neck cancer, especially
rhinopharynx lymphoepithelioma after combined chemotherapy
[20]. Other injuries involve the glossopharyngeal nerve with swal-
lowing impairment; vagus nerve after thoracic RT for breast [20]
and head and neck cancers [11]; recurrent laryngeal nerve with
larynx palsy after thoracic RT for thyroid tumour and spinal acces-
sory nerve with sternocleidomastoid and trapezius muscle palsy
[21]. Facial paralysis occurs after RT for parotid cancer [22].
Trigeminal neuropathy develops after cavernous sinus tumour
irradiation, mainly meningioma and chordoma [23], or essential
trigeminal neuralgia.
Cranial nerve neuromyotonia is a rapid muscular contracture,
tonic, progressive and involuntary, with relaxation delayed by
radiation-induced neuronal hyperexcitability, comparable to myo-
kymia observed in plexopathy with complex repetitive electro-
myogram discharges in muscles. It is characterised by
contraction lasting from a few seconds to minutes several times
a day, sometimes with a trigger factor [22], corresponding to dam-
age to the neuronal membrane which leads to cellular hyperexcit-
ability and abnormal repeated discharges.Axial neurological injury is a rare complication
Dropped head syndrome, late-onset cervico-scapular muscle
atrophy combined with cervical paraspinal and shoulder girdle
muscle weakness, has been reported up to 25 years after upper dia-
phragmatic RT for lymphoma in a small series of 2–15 patients
[24,25]. Apart from cervical pain, sensory function is preserved.
We have recently reported the case of a patient who developed aradiation-induced camptocormia after total lymphoid RT for lym-
phoma [26]. Asymmetric diaphragmatic weakness secondary to
phrenic nerve paralysis is very rare, initially described after cervi-
cal high-dose RT for head and neck cancer or more recently low-
dose mantle RT for Hodgkin’s disease [27].Upper limb injury with classic progressive brachial plexopathy
The main upper limb RIPN is chronic brachial plexopathy.
Delayed progressive radiation-induced brachial plexopathy (RIBP)
RIBP is a progressive injury in the axillary-supraclavicular
ipsilateral node volume after RT for breast cancer (Fig. 2). Time
to onset ranges from several months to decades with a mean
incidence of 1.8–2.9% per year [7,28]. During past decades, three
waves of RIBP incidence occured in accordance with the irradiation
technique at that period (Table 1a and b): 1950s with 60 Gy total
dose axillary-supraclavicular delivered using 5 Gy/fr followed by
66% RIBP [10,12]; 1960s with 45–50 Gy using 4 Gy/fr and patient
removal between each RT ﬁeld (overlapping) followed by 50% RIBP
[8,12]; 1970s–1980s with 45–50 Gy using 3 Gy/fr followed by
10–15% RIBP [12,28–30], then less than 5% [31]. The incidence of
RIBP today is <1–2% in patients receiving usual plexus total doses
<55 Gy [7,32].
More rarely RIBP is seen in apical lung [33] or head-neck [34]
cancers after hot spot total dose in relation to intensity-modulated
radiation therapy (IMRT) or stereotaxic body radiation therapy
(SBRT) and in Hodgkin’s disease with bilateral neuropathy after
mantle irradiation with only 40 Gy using 2 Gy/fr but a large vol-
ume [35–38] (Table 1c).
Several neurological publications have reported RIBP
[36,37,39–43]. Clinically, RIBP begins with subjective paraesthesia
or dysaesthesia which usually decreases with the development of
hypoaesthesia then anaesthesia. The pressure of a zone of axillary
and/or supraclavicular induration can trigger this paraesthesia
(Tinel’s sign). Neuropathic pain is generally rare and moderate,
except after failure of neurolysis. Motor weakness is progressive,
often delayed by several months, and then associated with fascic-
ulations and amyotrophy. The topography of symptoms varies
with the level of plexus damage, in relation with the irradiation
technique used, predominating at the upper or lower plexus. It
frequently starts at the median nerve, simulating carpal tunnel
syndrome, before spreading progressively to the forearm and then
the upper arm. Onset is often insidious, occurring over several
months or years. Intensity is variable, but progressively increases,
and after several years may result in paralysis of the upper limb
in a range of 0.2–5 years from the ﬁrst signs to hand paralysis
[43]. Rapid neurological worsening is possible after trauma such
as unusual traction on the affected limb, notably carrying of heavy
loads [2], thorax parietal surgery or upper limb lymphangitis. Skin
and muscular atrophy are combined, notably after previous ortho-
voltage or cobalt RT, with subcutaneous ﬁbrosis of the axillary-
supraclavicular area, and subcutaneous calciﬁcations or sterno-cla-
vicular osteonecrosis (Fig. 2a). Arm lymphoedema, which was fre-
quent in older studies, is strongly linked to combined extensive
lymph node dissection and high RT dose and is not predictive of
RIBP, but may enhance upper limb nerve compression.
Electroneuromyography identiﬁes the level of plexus injury
[44]. The initial anomaly is an alteration of the sensory potentials
of the median nerve in the ﬁngers, which discounts an involvement
proximal to the dorsal root ganglia (cervical) where the sensory
potentials are preserved. The decrease in amplitude of the motor
potentials generally starts in the thenar muscles (thumb). The
nerve conduction is normal or slightly reduced, compared with ax-
onal loss. A proximal conduction block of the motor ﬁbres is often
detected [41,45], reﬂecting focal demyelination whose origin may
Fig. 2. Radiation-induced brachial plexopathy (RIBP): (2a) a 74-year-old woman with left breast cancer 41 years ago was treated by breast (RT ﬁeld black dotted line) and
axillary-supraclavicular (RT ﬁeld black full line) irradiation followed by mastectomy: she developed arm lymphoedema, supraclavicular ﬁbrosis and RIBP (plexus along the
white dotted line) showing progressive sensory and motor upper limb signs for 4 years. (2b) Corresponding MRI in frontal view with supraclavicular and axillary compressive
ﬁbrosis without cancer recurrence.
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its role in the motor deﬁcit may explain why in some cases there is
a contrast between the severity or weakness and the absence of ax-
onal loss, either clinically (absence of amyotrophy) or electrophys-
iologically. Myokymic discharges are of great diagnostic value
when present as they are highly suggestive of a radiation-induced
effect. The main differential diagnosis of axillary tumour is based
on MRI (STIR sequence) (Fig. 2b) and PET-scan to rule out a tumour
recurrence characterised by an intense hypermetabolic zone in the
plexus and, if any, combined sites of metastatic cancer [13,46,47].Early transient RIBP
Early transient RIBP occurring within the year following breast
cancer irradiation is rare: 8 women with acute brachial plexopathy
out of 565 in a range of 2–14 months after an average supraclavic-
ular-axillary dose of 50 Gy in 1970s RT [48] and in 16 women with
acute RIBP out of 1117. 80% of these acute RIBP completely re-
solved [49]. A case of transitory RIBP has been reported, after
43 Gy mantle irradiation for Hodgkin’s disease, at one month
(duration of symptoms 6 months) and at 17 months (duration of
symptoms 6 months) with complete recovery [50]. Initial signs in-
clude distal paraesthesia with proximal pain. Moderate motor def-icit occurs straight away or in the following months, with
worsening. After 3 to 6 months of stability, neurological signs re-
gress, often completely. The direct and transient effect on Schwann
cells, which causes reversible demyelination, may be causal, as
suggested by some experimental data [51], while another hypoth-
esis concerns the role of compression caused by reversible radia-
tion-induced oedema.
Ischaemic RIBP
Ischaemic RIBP is an exceptional neuropathy of sudden onset,
with absence of secondary worsening. Only two cases of ischaemic
RIBP following RT related to acute ipsilateral occlusion of the sub-
clavicular artery have been reported [52].Lower limb injury
Less known, lower limb RIPN is rare, and was ﬁrst described
after testicular irradiation.
Delayed progressive lumbosacral radiculoplexopathy (RILP)
The term lumbosacral radiculoplexopathy is preferred to lum-
bosacral plexopathy, which is used by analogy with brachial
Table 1
Chronic radiation-induced brachial plexopathy (RIBP) after shoulder girdle radiotherapy.
(1a) For breast cancer: incidence in large retrospective trials
Series
Breast cancer
[Ref.]
Supraclavicular-axillary RT: total dose (size: dose/fraction)
[±reconstructed plexus dose]
RIBP incidence: number BP/total patients (%) RIBP latency period
(years) median
Stoll 66 [10]
RT (1958–62)
2 series
(a) 63 Gy/12fr/25d (5.25 Gy/fr) Co [55 Gy]
(b) 57.7 Gy/11fr (5.25 Gy/fr) [51] comorbidity:
RM, compressive lymphoedema in 58%(a)25%(b)
(a) 24 BP/33 pts (73%) complete paralysis and
sensory signs in 6
(b) 13 BP/84 pts (15%) complete paralysis in 1
(a) 14 mths
(b) 19 mths
1.3 y (0.5–2.5 y)
Westling 72 [8]
RT (1963–65)
44 Gy/11fr/23d (4 Gy/fr) isodose 130%/plexus.
Axillar ﬁeld with elevated arm [54]
comorbidity: RM, lymphoedema
31 BP/71pts (44%)
sensorimotor signs
3 y
1–4 y for 20
5–9 y for 8
10–22y for 6
Johanson 02 [12]
RT (1963–68)
3 series
(a) 44 Gy/11fr/3wk (4 Gy/fr) [80]
(b) 44 Gy/11fr (4 Gy/fr) Co-e- [82]
(c) 45 Gy/15fr (3 Gy/fr) Co-e- [63] Gyeq in smaller ﬁeld sizes
comorbidity: RM
(a) 45 BP/71 pts (63%)
(b) 11 BP/23 pts (48%)
(c) 8 BP/56 pts (14%)
complete paralysis/150 pts: 30% at
5 y, 50% at 15 y, 67% at 30 y
(a) 3y (1–19)
(b) 4 y (1–12)
(c) 5 y (1–18)
(a) Incid 41%/y
Basso-Ricci 80 [31]
RT 1965–72
RM
55 Gy/?fr/40d (>2 Gy/fr) [60]
16 BP/490 pts (3.2%)
+ others 26 BP
drugs test (worse/vasodilators)
<2 y for 19
2–4 y for 10
>4 y for 13
Pierce 92 [45]
RT (1968–85)
RT 2- or 3-ﬁeld technique:
48–54 Gy/25fr (2–2.5 Gy/fr) [50]
comorbidity: SM + CT
(a) 0 BP/507 pts 2-ﬁelds
(b) 20 BP/1117 pt (0.2%) 3ﬁelds
16 acute + chronic and severe in 4
0.9 y
(0.1*–6.4 y)
Rawlings 83 [32]
RT 1967–74
RT 1967–74
RT 1969–80
45 Gy/18fr (2,5–3.3 Gy/fr) ± boost
– exclusive RT [79] french technic
– SM + RT [51]
– BCS + RT [51]
overlapping post ﬁeld/supraclav
25 BP/1354 pts (1.8%)
9/245 (3.7%) for D > 60 Gy
11/650 (1.7%)
5/459 (1.1%) sensorimotor
neurolysis in 6
0.5–10 y
3.5 y
4.5 y
3 y
Olsen 90 [29]
RT (1977–82)
36.6 Gy/12fr/40d (3 Gy/fr); 2fr/wk
comorbidity: SM (N dissection > 6), concomitant CT
(a) 28 BP/79 pts (35%)
Mild in 13
Severe in 15
0.3*–5 y
Olsen 93 [30]
RT (1982–90)
SM (11 nodes), sequential CT
50 Gy/25fr/38d (2 Gy/fr)
(b) 19 BP/161 pts (12%)
Mild in 12
Severe in 7
Months?
Powell 90 [7]
RT (1982–84)
2 series
SM or BCS + RT 3- or 4-ﬁeld technique (80% isodose) pt turned
(a) 51 Gy/15fr/6wk(3.4 Gy/fr) [46]
(b) 60 Gy/30fr (2 Gy/fr) [54]
0 BP with 2 Gy/fr and 4-ﬁelds
(a) 17 BP/338pts (5%)13BP/3-fd
(b) 1 BP/111pts (3-fd)
0.8–4 y
incidence 1.8%/y
Bajrovic 04 [28]
RT (1980–93)
SM or BCS, sequential CT
60 Gy/20fr (3 Gy/fr) Co
with [52] 2.6 Gy/fr plexus
19 BP/ 140 pts (14%)
severe in 2% at 5 y; 5.5% at 10 y;
12% at 15 y; 19% at 19 y
7.3y (2.5–18 y)
incidence 2.9%/y
5 y:4%; 10 y:25%
(1b) For breast cancer: incidence in case reports
Cases
Breast cancer [Ref.]
Supraclavicular-axillary RT:
total dose (dose/fraction)
RIBP incidence
number BP/total patients
RIBP latency period (years)
median
Pritchard 01 [39]
RT 1970–95?
Various postoperative techniques
with lymphoedema
including R.A.G.E. patients
HBO test
34 BP 3 y
64 y for 20
5–9 y for 8
>10 y for 6
Kori 81 [36] 6000R?
neurological serie
13 BP sensorimotor <1 y for 4?
>1 y for 9?
Roth 88 [41]
RT 1973
59 Gy (2.5 Gy/fr)
RM + carpal tunnel syndrome
traumatic stretching disclosure
neurological series
1 BP sensorimotor
cramps, myokymia, pain, conduction blocks on EMG
neurolysis (worse)
9 y
Fardin 90 [42]
RT 1964–81
RM
50 Gy/30d (2.5 Gy/fr)
neurological series
10 BP sensorimotor and progressive
+ 3 acute sensitive
7 y (3–15 y)
68 mths for 3
Killer 90 [37] ?
Neurological series
7 BP sensorimotor
plexus surgery test
2 y (0.5–7)
Fathers 02 [43] BCS
50 Gy/16fr (3 Gy/fr)
neurological series
33 BP sensorimotor and proximo/distal
time to hand weakness : 1.2 y (0.2–5 y)
1.5 y
0.5–20 y
(continued on next page)
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Table 1 (continued)
(1c) For head-neck and lung cancers, for Hodgkin’s disease
Irradiated cancer Series/cases [Ref.]
RT date
Supraclavicular-axillary RT:
total dose, dose/fraction
[±plexus dose]
RIBP incidence
nb BP/total (%)
RIBP latency period (years)
median
Hodgkin disease Pezzimenti 73 [35] Subclavicular
± salvage
2 BP 0.2 y
Kori 81 [36] ? 3 BP ?
Killer 90 [37] ?
+ lymphoedema in 3/5
5 BP sensorimotor Median 6 y
(2–18 y)
Wadd 98 [38] 40 Gy/20fr mantle RT
± salvage lumbar RT/chemotherapy
2 BP nilat or bilat
sensorimotor
12–19 y
Lung apical Ca Kori 81 [36] ? 3 BP/lung Ca
2 BP/thyroid Ca
Forquer 08 [33] 57 Gy (18 Gy/fr) 3–4fr/8d SBRT stereotaxic 7 BP/37 pts (19%) Median 0.6 y
(6–23 mths)
Head Neck Ca Chen 10 [34]
RT (2007–10)
69 Gy [63–78] exclusive or IMRT postoperative
[Dmax > 74 Gy]
22 BP/145 pts (15%) sensorimotor Median 1.5 y
(6–30mths)
RM, radical mastectomy with extended lymph node dissection; SM, simple mastectomy with lymph node dissection levels I–II; BCS, breast conserving surgery with lymph
node dissection levels I–II; CT, adjuvant chemotherapy; Co, cobalt 60; Gy, gray; d, day; fr, fraction; 3-fd, three-ﬁeld technique (with patient move and overlap risk); y, year.
* means: acute BP.
278 Radiation-induced neuropathyplexopathy, but does not correspond to the clinical reality of the
anatomic lesions that simultaneously affect in a given volume
the lumbosacral spinal cord, the nerve roots, the lumbosacral
plexus and the large nerve trunks.
Some 75 RILP cases of the lower limbs (Table 2a) have been re-
ported in a range of 0.4–25 years after external RT for testicular
cancer [11,53–63] and a range of 1–24 years after RT for lym-
phoma [3,13,59,62,64–67]. The current ‘‘over-representation’’ of
Hodgkin’s disease seems to be related to the efﬁcacy of older
treatments. These survivors are then susceptible to late-onset
neuropathy, delayed further because the total irradiation dose
was moderate (40–45 Gy using 2 Gy/fr) but sufﬁcient to be toxic,
given the large ﬁeld volume covering the lumbo-aortic, iliac and
inguinal lymph node chains, emphasising the importance of the
volume of nerve irradiated in generating radiation-induced neur-
opathies (Fig. 3).
After pelvic RT (Table 2b) with more than 60 Gy, RILP cases in-
clude 24 after RT for cervical carcinoma with intracavitary radium,
comorbidities or combined extensive node dissection [13,14,68–
73], and cases for rectal [74,75] and bladder cancers [70]. In a
long-term follow-up after a median dose of 73 ‘‘Gy-equivalents’’
in RT for retroperitoneal-paraspinal sarcomas, 13 out of 53 patients
(25%) developed neurotoxicity in a mean time of 7 years [76].
Intraoperative radiotherapy (IORT) has yielded substantial experi-
mental and clinical data. The high risk of RILP of sciatic and femoral
nerves limits this technique because of the perioperative delivery
of RT in a single high-dose fraction.
RILP occurs earlier after high-dose RT in a moderate volume
and later with moderate doses in a large volume. Although irra-
diation was delivered around the body median line, the usual
neurological deﬁcits are bilateral and asymmetric with initial
unilateral damage [59]. The onset of neurological signs is insid-
ious, with damage that is largely motor [58]. Unlike RIBP, the
sensory signs and paraesthesia are absent or noted very late,
in contrast to signs of peripheral neurogenic motor involvement,
such as amyotrophy and fasciculations. Central signs are lacking,
apart from possible associated medullar damage, and the handi-
cap progresses in severity after a few years. Subcutaneous
paraspinal muscle atrophy often corresponds to the previous
RT volume (Fig. 3a). Sudden worsening of the neurological deﬁcit
associated with lumbar pain may indicate vertebral compression
with underlying radiation-induced vertebral osteoporosis, nota-
bly following a fall because of walking difﬁculties. Intestinal
and/or urinary disorders are associated after pelvic RT, eitherby peripheral neurogenic damage or by pelvic ﬁbrosis. Disease
progression generally proceeds step-wise, with periods of stabili-
sation. Diagnosis, which is often difﬁcult, requires neuroradiolog-
ical examinations to rule out tumour invasion or narrowing of
the lumbar canal [13]. In the case of pure motor forms, the main
differential diagnosis is amyotrophic lateral sclerosis: it is not
rare for this initial diagnosis to be questioned because there is
no rapid progression of the motor deﬁcit to new territories or
the appearance of pyramidal syndrome. Electroneuromyography
objectiﬁes anomalies that usually affect several nerve roots,
while the sensory potentials are preserved. Decrease in sensory
potentials may be caused by radiation-induced damage to lymph
nodes, but may also reﬂect sequelae of chemotherapy with cis-
platin or taxol. Myokymia, as in RIBP, may indicate a radia-
tion-induced origin [65]. Lumbar MRI usually shows lesions of
osteoporosis of the vertebral bodies, which conﬁrms that the
adjacent nerve roots were included in the ﬁeld of RT. MRI does
not play a determinant role in a positive diagnosis, but does
eliminate tumour invasion or lumbar canal stenosis (Fig. 3b):
nodular enhancing lesions suggest leptomeningeal metastases.
Biopsy of the nerve root of the cauda equina shows ﬁbrotic le-
sions and vascular dilation corresponding to cavernomas [4]. Re-
cently, a new technique of a posteriori conformal RT with 3D-
dosimetric reconstitution has been used to conﬁrm diagnosis of
RILP of the lower limbs, and deﬁnes the anatomical regions that
have received a high radiation dose. In one report, a patient had
developed a pure, progressive motor deﬁcit of the lower limbs,
which was initially diagnosed as amyotrophic lateral sclerosis;
3D-dosimetric reconstitution showed that the spinal cord and
the lumbosacral nerve roots had in fact received an unplanned
dose of 52 Gy along a 7 cm segment [3].
Acute transient lumbosacral plexopathy
Transient lumbosacral plexopathy was recently described fol-
lowing L-ﬁeld (12th thoracic–5th lumbar vertebrae) RT for testicu-
lar cancer, after mild RT doses in 11 out of 346 patients. Seven
patients presented with bilateral paraesthesia, which lasted less
than three months, in the 6 months after RT using a median total
dose of 25 Gy, and four patients showed weakness lasting at least
one year, in a range of 3–9 years after a total dose of 36–40 Gy [77].
As described for transient RIBP, symptoms worsened over a few
months, then stabilised before regressing, often completely. A
few single cases have been reported after pelvic or lumbar RT with
45–55 Gy [13,75].
Table 2
Chronic radiation-induced radiculoplexopathy (RILP) after lumbo-pelvic girdle radiotherapy.
Irradiated cancer
(total)
Series/cases [Ref.]
RT date
Lumbo-sacral (volume) radiotherapy
total dose, dose/fraction,
[±plexus dose]
RIRP incidence
number/total patients (%)
RIRP latency period (years)
median
(a) Low and moderate dose levels in extended volume irradiation for testicular cancer and Hodgkin’s disease
Testicular Ca
(n = 54)
Maier 69 [11]
Greenﬁeld 48 [63]
RT (1944–65)
Retroperitoneal node dissection
lumbo-iliac [T11–L4] 200 KV
#48–53 Gy/12 wk
15 RP motor/313pts (5%) Mean 2y (0.4–13 y)
Schiodt 78 [53]
RT (1965–74)
>55 Gy/6 wk
lumbar [T11–L5] Cobalt
5 RP/99pts (5%) alive/156
treated
+ 5 acute*
Mean 1.5 y
mean 4 mths
Grunewald 92 [54]
RT (1964)
49 Gy (1.4 Gy/fr)/7 wk
lumbar + pelvis
1 RP motor 23 y
Kristensen 77 [55]
RT (1968–75)
#55 Gy/6 wk
lumbar [T11–L5] 6 MV
4 RP motor 0.4–1.3 y
Knap 07 [56]
RT (1964–73)
36–51 Gy (3 Gy/fr) [#60]
lumbar
and 59 Gy (2  1.6 Gy/d) in 1 pt
6 RP/94pts (6%)
+ 1 acute *
± 9 mixte
14 y (10–20 y)
9 mths
?
Horowitz 83 [57]
RT 1977
25 Gy lumbar-pelvis + salvage 30 Gy postop coeliac and
CT
1 motor 0.7 y/2nd RT
2 y/1st RT
Feistner 89 [58]
RT (1977–82)
45 Gy (2–3Gy/fr)/3–4 wk
lumbar + iliac/mediastine
3 RP motor 3–9 y
Lamy 91 [59]
RT (1970)
30 Gy lumbar and 30 Gy mantle 1 RP motor 12 y
Bowen 96 [60]
RT (1966–88)
40–50 Gy (1.7–2.2 Gy/fr)
lumbar T10–L4 ± iliac/mediastine
6 RP motor Mean 11 y
(3–25 y)
Tallasken 97 [61]
RT (1981–84)
36 Gy (2 Gy/fr)/3.5 wk lumbar
+ salvage 32 Gy/4 wk (0.9 Gy/fr)
1 RP motor 0.8 y/2nd RT
3.8 y/1st RT
Mathis 07 [62]
RT (1983)
Dose?
mantle–lumbar RT
1 RP motor 13 y
Hodgkin’s disease
(n = 20)
DeGreve 84 [64] 40 Gy/4 wk (2 Gy/fr)
mantle + lower-diaphragmatic
1 RP acute* 1.8 y regressive after
5 mths
Thomas 85 [13]
RT (1965–83)
40–50 Gy lumbar (2 Gy/fr) 5 RP Median 5 y
Lamy 91 [59]
RT (1974–82)
40 Gy
mantle + lower-diaphragmatic
2 RP motor 1.5–9 y
Lalu 98 [65] >40 Gy
mantle + lower-diaphragmatic
4 RP motor Mean 16.5 y
(6–24 y)
Hsia 03 [66]
RT (1978–84)
mantle 50 Gy
+ lower-diaphragmatic 44 Gy
3 RP motor 17–24 y
Mathis 07 [62]
RT (1975–96)
40–44 Gy/16fr (2.5 Gy/fr)
mantle + lower-diaphragmatic
2 RP motor 8.5–21y
Delanian 08 [67]
RT (1985–88)
36–40 Gy (2 Gy/fr)
mantle + lower-diaphragmatic co-morbidity
2 RP motor 9–10 y
Delanian 10 [3]
RT (1993)
45 Gy (2 Gy/fr)
mantle + lower-diaphragmatic heterogeneity in volume
[#52]
1 RP motor 10 y
(2b) High dose level in lumbo-pelvic volume irradiation for pelvic cancers
Gynaeco-logical
Ca
(n = 24)
Aho 1983 [64]
RT (1964–68)
Hysterectomy-node dissection
+ 50 Gy pelvis
+ radium ± 34 Gy parameter (1pt/2)
2 RP motor 8–14 y
Georgiou 93 [65]
RT?
50 Gy pelvis [#73 sacral]
+ 30 Gy radium (brachytherapy)
4 RP motor/2410pts (0.15%) 0.8*–2 y
Ashenhurst 77
[13]
RT 1969
40 Gy/14fr (2.85Gy/fr) pelvis
+ radium cervix 67 Gy/T [#82 ptA]
1 RP sensorimotor 0.5 y
Pettigrew 84 [66]
RT (1970–79)
50 Gy pelvis + radium
[#80]
2 RP motor 3.5–11.5 y
Thomas 85 [12]
RT (1965–83)
>50 Gy (2–3.5Gy/fr) pelvis
± radium
9 RP
sensorimotor
Mean 5 y
Glass 85 [67]
RT 1972
40 Gy pelvis [#80]
+ radium (lateral deviation)
1 RP unilateral 12y
Saphner 89 [68]
RT 1972–86
Uterine RT technique? 2 RP motor/1219pts (0.15%) 0.8 y*–14 y
Stryker 90 [69]
RT 1973–84
Lumbar node dissection
51 Gy/30fr (1.7Gy/fr) pelvis L4–L5
+ 36 Gy/ptA brachytherapy (caesium)
1 RP/313 pts sensorimotor 1 y
Lalu 98 [61] P45 Gy
lumbar + pelvic ± brachytherapy
2 RP sensorimotor 9–15 y
Rectal Ca Frykholm 96 [70]
RT 1979–93
25 Gy/5d (5 Gy/fr) 3 post ﬁelds 4 RP/443 pts
5 RP/59 pts
<1 y
Dahele 06 [71] Comorbidities (postop/CT/age):
+ 45 Gy + diabetes/rectal Ca
+ 55 Gy/anal Ca
2 RP motor 0.4 y*
(continued on next page)
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Table 2 (continued)
Irradiated cancer
(total)
Series/cases [Ref.]
RT date
Lumbo-sacral (volume) radiotherapy
total dose, dose/fraction,
[±plexus dose]
RIRP incidence
number/total patients (%)
RIRP latency period (years)
median
Sarcoma Pieters 06 [72] Combined RX-protons in (L2-coccyx)
[# 73 CGE Gy équivalents]
13 RP/53 pts (25%) 5 y
Bladder Ca Ashenhurst 77 [13]
RT (1965)
Alternated fx
67 Gy/24fr (2.8 Gy/fr)
1 RP sensorimotor 4 y
* Early transitory neurological symptoms followed by partial recovery.
Fig. 3. Lower limb radiation-induced radiculoplexopathy (RILP): (3a) clinical history: this 51-year-old man treated by 40 Gy total lymphoid irradiation for Hodgkin’s disease,
26 years ago, has RILP corresponding to lumbar muscle-subcutaneous atrophy (RT ﬁeld black full line); (3b) corresponding MRI in sagittal view with subcutaneous atrophy
(arrow), pagetoid vertebra (arrow), without cancer recurrence.
280 Radiation-induced neuropathyNerve trunk damage
The most common aetiology of neuropathy after lower limb
irradiation is tumour recurrence and radiation-induced ﬁbrotic
compression, best discriminated by MRI. Severe isolated cases of
radiation-induced injury of the nerve trunk (sciatic, crural) after
external irradiation of the thigh have been reported [78]. In one
case, a posteriori 3D-dosimetric reconstitution identiﬁed risk fac-
tors such as irradiation (66 Gy) over a 25 cm stretch of a nerve
and large surgical sarcoma resection of the thigh, exposing the sci-
atic nerve at the surface of the irradiated volume [79]. In another
case, salvage RT (30 Gy) overlapped the volume irradiated postop-
eratively (50 Gy) one year before. Other cases of RIPN have been re-
ported in the long-term follow-up to conservative treatment of
extremity sarcomas: with brachytherapy implants in four cases
(9%) at 6–20 months [80]; after 20 Gy single-dose boost electron
IORT in combination with external 45 Gy RT in nine out of 15 pa-
tients at 10 years [81]; after 15 Gy IORT in 24 out of 195 survivors
at 94 months [82]. Moreover, indirect femoral nerve paresis by scar
tissue compression has also been described in patients irradiated
along the inguinal region and thigh nerve trajectory [83,84].RIPN treatments
In today’s clinical practice, RIPN treatment is symptomatic. A
curative strategy has yet to be deﬁned; however the best approachis always prevention in respect of RT limits [85] by reducing total
RT dose, dose per fraction and RT volume every time if possible,
while identifying patients with serious comorbidities.Symptomatic treatment
Pain, if any, is usually treated with non-opioid analgesics, ben-
zodiazepines, tricyclic antidepressants and anti-epileptics. Benzo-
diazepines are used for paraesthesia and quinine for cramps.
Membrane-stabilising drugs (carbamazepine) may reduce nerve
hyperexcitability, like myokymia. Neurolysis is an additional surgi-
cal manipulation that can worsen nerve wall ischaemia, whereas
mechanical separation from compressive ﬁbrosis may in theory re-
lease trapped nerves; and surgical methods have never proven use-
ful in the management of RIPN. Vitamins B1–B6 are often used
routinely, but detailed data are lacking. Physical therapy is valu-
able in maintaining function and preventing joint complications,
which cause pain and hamper movement. It is important to pre-
vent any stretching of a plexus immobilised by ﬁbrosis, notably
by avoiding the carrying of heavy loads and extensive movements,
which are likely to cause sudden neurological decompensation.Restriction of aggravating factors
Removal of inciting stimuli is helpful in controlling the progres-
sion of RIPN [85]. First, removing co-morbidity factors by (i) general
S. Delanian et al. / Radiotherapy and Oncology 105 (2012) 273–282 281measures as controlling diabetes and high blood pressure; (ii) stop-
ping alcohol abuse, avoiding ﬁbrogenic drugs and statins (potential
neuromuscular toxicity); and (iii) by local measures consisting in
avoiding any local trauma in the irradiated volume, such as new
surgery or biopsy (haematoma, infection). Second, controlling acute
inﬂammation with corticosteroids, which are of value in reducing
the acute inﬂammation associated with RIF and should ﬁrst be
used to circumscribe the ﬁbrotic volume and density, despite lack
of any objective efﬁcacy in reduction of ﬁbrosis and nerve lesions
[86,87].Disease-modifying agents
The literature is poor concerning the treatment of RIPN.
Vascular approach
Evidence for the beneﬁt of hyperbaric oxygen (HBO) in RIF is not
apparent [85,88] and the literature is dominated by small trials
with ill-deﬁned recording of complications. HBO reduces tissue oe-
dema and stimulates angiogenesis, ﬁbroblast proliferation and col-
lagen formation in irradiated hypoxic tissue, which paradoxically
may enhance ﬁbrotic properties. In a study of 32 women who
underwent breast-conserving irradiation and 12 controls, after 25
HBO sessions and median follow-up of 9 months, signiﬁcant reduc-
tion in pain, oedema and erythema was observed, but ﬁbrosis and
telangiectasia were not affected [89]. There was no evidence that
HBO was clinically beneﬁcial in 34 patients with RIBP at 12 months
of follow-up, although it may improve the warm sensory threshold
[39]. Because of vascular changes and ischaemia, heparin and war-
farin have been used in an attempt to halt progression of radiation
necrosis [90].
Fibrosis/atrophy
Although pathogenesis of RIPN initially involves vascular mech-
anisms, ﬁbrosis and atrophy are the main targets for therapeutic
interventions. It has been known for two decades now that com-
bined pentoxifyllin-tocopherol (PE) signiﬁcantly reduces RIF due
to their synergistic clinical and biological properties [91,92]. In a
series of patients treated with PE for superﬁcial ﬁbrosis, 8 patients
with RIBP showed neurological symptom stabilisation, but no
improvement at 18 months [85]. More recently, 10 out of 11 pa-
tients treated for cerebral radionecrosis after stereotactic RT
showed signiﬁcant improvement after PE combination [93]. Clodr-
onate, a bisphosphonate, inhibits osteoclastic bone destruction
with anti-inﬂammatory effects, and inhibits macrophagic myelin
nerve destruction in rats [85]. Recently, clodronate, when com-
bined with pentoxifylline-tocopherol (PENTOCLO), healed 54 pa-
tients with refractory osteoradionecrosis in a median of 9 months
[94]. Moreover, neurological symptoms were reduced by half in
two patients with progressive RILP after 3 years of PENTOCLO
treatment [67], results that have led to an ongoing phase III ran-
domised clinical trial in France (NCT01291433).Conclusion
Knowledge of RIPN complications has improved and we can
now distinguish sub-types and unravel the complex pathophysiol-
ogy. However, more systematic descriptions of the epidemiology
and history of these neuropathies are required, and we need longi-
tudinal studies in large cohorts of patients. Diagnostically, progress
in structural and functional imaging techniques has enabled better
differentiation between radiculopathy and a recurrent tumour.
Improved understanding and earlier diagnosis of these complica-
tions, before the lesions become progressive and irreversible, is
particularly important given the recent emergence of newtherapeutic leads. Cancer patients are surviving for many years
and so the management of late treatment-related complications
that reduce their quality of life has become a public health priority.References
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